Preparation method of HLA-A0201-restricted anti-HPV (human papillomavirus) antigen-specific CTL

A 1. HLA-A0201, restrictive technology, applied in the field of biotechnology development and application research, can solve problems such as unknown, long time for in vitro separation and amplification, increased pollution, etc., and achieve the effect of simple operation

Active Publication Date: 2012-10-10
江苏得康生物科技有限公司
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0017] 2. Differences in CTL phenotype and function
[0035] ②TIL separation, the acquisition and identification methods of CTL clones are complicated, and there are many and complicated cell components in the tumor tissue, and the time to separate cells is long, usually more than 1 month;
[0036] ③TILs are mixed with CD4+CD25+Treg subsets, which can inhibit the expansion efficiency of CTLs;
[0037] ④ Due to the long time of in vitro separation and amplification, the chance of contamination is increased
[0039] ① The introduction of exogenous plasmids (retroviruses or lentiviruses, etc.) brings certain risks to clinical application;
[0040] ②Endogenous TCR interference, the imported TCR

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method of HLA-A0201-restricted anti-HPV (human papillomavirus) antigen-specific CTL
  • Preparation method of HLA-A0201-restricted anti-HPV (human papillomavirus) antigen-specific CTL
  • Preparation method of HLA-A0201-restricted anti-HPV (human papillomavirus) antigen-specific CTL

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0142] Example 1: HPV16E7 11-20 Antigen-specific CTL preparation

[0143] 1. Preparation for patients with HLA-A201+HPV16+cervical cancer

[0144] Take 1ml of peripheral anticoagulant blood from the patient, add FITC-labeled HLA-A2-mAb (American BD Company, product number 551285, the same below), and detect the expression of HLA-A2 (abbreviation of HLA-A201, the same below) by flow cytometry; Cancer patients were tested for HPV, and HPV16-positive patients were selected. Cervical cancer patients with simultaneous expression of HLA-A2 and HPV16 were selected.

[0145] 2. Antigen peptide synthesis

[0146] HPV16E7 polypeptide, the position is 11-20, and the sequence is YMLDLQPETV (SEQ ID NO.1) 10 peptide (hereinafter referred to as HPV16E7 11-20 Polypeptide), chemically synthesized (Shanghai Gill Biochemical Co., Ltd.), fully dissolved in sterile double distilled water, the peptide concentration is 5mg / ml, and stored in -80°C in aliquots.

[0147] 3. PBMC collection

[014...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a preparation method of HLA-A0201-restricted anti-HPV (human papillomavirus) antigen-specific CTL. The preparation method comprises the following steps of: collecting peripheral blood mononuclear cells through apheresis, and enriching and purifying CD8+T lymphocytes; stimulating the CD8 + T lymphocytes by mature dendritic cells of a loaded HLA-A0201-restricted HPV antigen polypeptide; and promoting the T-cell growth through combined use of rhIL-2 and rhIL-7; purifying a target CTL by a Tetramer marking method and a flow cytometry sorting technique; stimulating the growth of the target CTL by solid phase packaged anti-human CD3 monoclonal antibody and IL-2; adding autologous PBMCs (peripheral blood mononuclear cell) after gamma-ray irradiation for enhancing activation of the target CTL; and adding rhIL-15, cultivating and amplifying, and collecting and identifying. The target CTL prepared by the prepared method has high purity, high proliferative capacity, high killing activity and a high CTL-CM ratio and can be applied to immunotherapy of tumors and the like.

Description

technical field [0001] The invention belongs to the field of biotechnology development and application research, and relates to a preparation method of HLA-A0201-restricted anti-HPV antigen-specific CTL. Background technique [0002] 1. HPV infection and cervical cancer [0003] Cervical cancer is the third most common malignant tumor among women in the world. There are about 500,000 new cases of cervical cancer every year in the world, and nearly 274,000 patients die from the disease. A large number of studies have shown that the occurrence of cervical cancer is closely related to the persistent infection of high-risk human papillomavirus (human papillomavirus, HPV). More than 100 types of HPV-DNA have been isolated, more than 30 of which are related to cervical lesions. According to the size of its pathogenicity, it is divided into low-risk type and high-risk type, and the high-risk type mainly leads to the occurrence of cervical cancer, and HPV16 / 18 is more common, and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N5/0783
Inventor 时宏珍
Owner 江苏得康生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products